Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1183/13993003.02426-2016</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:34491883">http://nrs.harvard.edu/urn-3:HUL.InstRepos:34491883</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure

Bram Rochwerg, Laurent Brochard, Mark W. Elliott, Dean Hess, Nicholas S. Hill, Stefano Nava and Paolo Navalesi (members of the steering committee); Massimo Antonelli, Jan Brozek, Giorgio Conti, Miquel Ferrer, Kalpalatha Guntupalli, Samir Jaber, Sean Keenan, Jordi Mancebo, Sangeeta Mehta and Suhail Raoof (members of the task force)

@ERSpublications
ERS/ATS evidence-based recommendations for the use of noninvasive ventilation in acute respiratory failure http://ow.ly/NrqB30dAYSQ


ABSTRACT Noninvasive mechanical ventilation (NIV) is widely used in the acute care setting for acute respiratory failure (ARF) across a variety of aetiologies. This document provides European Respiratory Society/American Thoracic Society recommendations for the clinical application of NIV based on the most current literature.

The guideline committee was composed of clinicians, methodologists and experts in the field of NIV. The committee developed recommendations based on the GRADE (Grading, Recommendation, Assessment, Development and Evaluation) methodology for each actionable question. The GRADE Evidence to Decision framework in the guideline development tool was used to generate recommendations. A number of topics were addressed using technical summaries without recommendations and these are discussed in the supplementary material.

This guideline committee developed recommendations for 11 actionable questions in a PICO (population–intervention–comparison–outcome) format, all addressing the use of NIV for various aetiologies of ARF. The specific conditions where recommendations were made include exacerbation of chronic obstructive pulmonary disease, cardiogenic pulmonary oedema, de novo hypoxaemic respiratory failure, immunocompromised patients, chest trauma, palliation, post-operative care, weaning and post-extubation.

This document summarises the current state of knowledge regarding the role of NIV in ARF. Evidence-based recommendations provide guidance to relevant stakeholders.

This article has supplementary material available from erj.ersjournals.com

Received: Dec 09 2016 | Accepted after revision: June 15 2017

This document was endorsed by the ERS Executive Committee in July 2017 and approved by the ATS Board of Directors in June 2017.

The guidelines published by the European Respiratory Society (ERS) incorporate data obtained from a comprehensive and systematic literature review of the most recent studies available at the time. Health professionals are encouraged to take the guidelines into account in their clinical practice. However, the recommendations issued by this guideline may not be appropriate for use in all situations. It is the individual responsibility of health professionals to consult other sources of relevant information, to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and the patient’s caregiver where appropriate and/or necessary, and to verify rules and regulations applicable to drugs and devices at the time of prescription.

Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

Copyright ©ERS 2017

Introduction

The purpose of the current European Respiratory Society (ERS)/American Thoracic Society (ATS) guidelines is to provide evidence-based recommendations on the application of noninvasive ventilation (NIV) in acute respiratory failure (ARF). We also address some practical issues relating to NIV application and maintenance. As much as possible, we pose questions in a PICO (population–intervention–comparison–outcome) format and use the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methodology to assess the certainty of the evidence. However, some of the questions were best addressed with technical summaries without formal recommendations. These summaries and a brief narrative literature review are provided in the supplementary material. In this document, NIV includes noninvasive variable positive airway pressure (most commonly "bilevel") devices consisting of a higher inspiratory positive airway pressure and a lower expiratory pressure as well as continuous positive airway pressure (CPAP) delivered using various nasal, oronasal and facial interfaces.

Methods

Committee composition

The guideline committee was composed of clinicians and experts in the field of NIV. Members were either physicians (pulmonologists or intensivists) or respiratory therapists. Two clinician-methodologists with expertise in evidence synthesis and the guideline development process provided GRADE support. Committee members signed a confidentiality agreement and disclosed all potential conflicts of interest according to the policies of the ERS and ATS.

Evidence review and development of clinical recommendations

The committee developed recommendations based on the GRADE methodology for each actionable question [1]. The committee chose the clinical questions based on perceived clinical importance and prioritisation based on sampling of the committee members. The methodologists performed pragmatic literature searches, screening of potential studies for inclusion, pooling of outcome data when appropriate and evidence summary/analysis. The methodologists designed a search strategy for each question using medical subject heading keywords and text words limited to human studies or nonindexed citations and articles in English or in any language with English abstracts. The Ovid platform was used to search MEDLINE and the Cochrane Registry of Controlled Trials (CENTRAL). A single reviewer screened all potential references for inclusion. The last update of the search was performed in November 2016.

The committee selected outcomes of interest for each question and these were explicitly rated for their relative importance (from the perspective of a patient with respiratory failure) from "not important" to "critical" [2]. Ranking outcomes by their relative clinical importance helps to focus on those that are most relevant to patients and may lead to improved clarification during potential disagreements in decision making. Rankings of all outcomes were agreed upon through consensus of the committee. The critical outcomes prioritised for this guideline effort were: mortality, need for intubation and nosocomial pneumonia. These prioritised outcomes applied to all actionable questions except the one pertaining to palliation (Question 7), for which the panel prioritised patient-reported dyspnoea as the critical outcome.
of interest. For questions where critical outcome data was unavailable, other important outcomes are presented as part of the evidence synthesis.

The certainty in effect estimates for each outcome were then categorised as high, moderate, low or very low according to the GRADE process. The GRADE Evidence to Decision framework in the guideline development tool was used to help facilitate discussion around each recommendation [3, 4]. The Evidence to Decision framework ensures each of the following factors are considered in recommendation development: quality of the evidence, balance of desirable and undesirable consequences of compared management options, assumptions about the values and preferences associated with the decision, implications for resource use and health equity, acceptability of intervention to stakeholders, and feasibility of implementation. Recommendations and their strength were decided by consensus. The entire committee agreed on the final wording of each recommendation and rationale with further qualifications for each recommendation (e.g. subgroup considerations, justification and implementation considerations).

Each recommendation was designated as “strong” or “conditional” [5]. As outlined by GRADE, we used the phrasing “we recommend” for strong recommendations and “we suggest” for conditional recommendations. Table 1 provides an interpretation of these recommendations by stakeholders (patients, clinicians and healthcare policy makers). Further description and details of the methodology used to compose these guidelines can be found in the supplementary material.

**Manuscript preparation**

For each of the recommendations, a narrative summary was provided for contextualisation and then a justification section, which summarised pooled estimates of effect, certainty of evidence and relevant Evidence to Decision framework factors. The committee was divided into pairs or groups of three who were responsible for composing individual components of the guidelines (organised by recommendation). Articles cited in the narrative reviews were selected by the authors to highlight the evidence relied upon to arrive at the recommendation (usually the largest, most significant or most directly relevant to our PICO question). These manuscript components were then collated by the executive to ensure cohesiveness and distributed to the entire committee for vetting and review. Feedback was provided by electronic communication. The final approved version was submitted to each co-sponsoring professional society for peer review.

**Confidentiality agreement and conflict of interest management**

Committee members signed a confidentiality agreement and disclosed all potential conflicts of interest according to the ERS policies. The co-chairs were responsible for reviewing all potential conflicts of interest of committee members with the staff of the ERS. After review, there was no limitation of committee member’s involvement in the recommendation formulation process. The methodologists participated in discussions, but were nonvoting participants.

**How to use these guidelines**

These ERS/ATS evidence-based guidelines for the use of NIV in critically ill patients provide the basis for stakeholders to make rational, informed decisions. Clinicians, patients, third-party payers, institutional

<table>
<thead>
<tr>
<th>TABLE 1 Interpretation of strong and conditional recommendations for stakeholders (patients, clinicians and healthcare policy makers)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Strong recommendation</strong></td>
</tr>
<tr>
<td>For patients</td>
</tr>
<tr>
<td>For clinicians</td>
</tr>
<tr>
<td>For policy makers</td>
</tr>
</tbody>
</table>
review committees, other stakeholders or the courts should never view these recommendations as dictates. No recommendation can take into account all of the often-compelling unique individual clinical circumstances. Therefore, no one charged with evaluating a healthcare professional’s actions should view these recommendations as absolute. Statements regarding the underlying values and preferences as well as qualifying remarks accompanying each recommendation are integral to the recommendations and serve to facilitate more accurate interpretation; they should be included when quoting recommendations from these guidelines.

**PICO questions and recommendations**

**Question 1: Should NIV be used in COPD exacerbation?**

Chronic obstructive pulmonary disease (COPD) exacerbations are a very common reason for admission to hospital. Approximately 20% of patients hospitalised for COPD present with [6] or develop hypercapnic respiratory failure [7], which is an indicator of an increased risk of death [6–8]. ARF leading to acute or acute-on-chronic respiratory acidosis, later referred to in this guideline as acute respiratory acidosis, develops when the respiratory muscles fail to achieve adequate alveolar ventilation despite high levels of diaphragmatic activity [9]. It is likely that hyperinflation during exacerbation also contributes to respiratory muscle compromise. When faced with a load that exceeds the capacity of the respiratory muscle pump, a rapid shallow breathing pattern develops which is characterised by an increased respiratory rate with small tidal volumes. Although this is not always beneficial in terms of respiratory muscle energy expenditure, this pattern seems to have a complex pathophysiological mechanism and occurs at the expense of adequate alveolar ventilation. As a consequence, the level of arterial carbon dioxide (CO₂) rises and respiratory acidosis ensues. Measuring respiratory rate, observing chest and abdominal wall movement, and obtaining a sample of arterial blood are therefore key in the initial assessment of the patient at risk of acute respiratory acidosis (pH ≤7.35). Many patients with COPD are hypercapnic at baseline and the development of acidosis indicates acute-on-chronic hypercapnic respiratory failure.

Bilevel NIV may be considered in COPD patients with an acute exacerbation in three clinical settings [10]:

1) To prevent acute respiratory acidosis, i.e. when the arterial CO₂ tension (Paco₂) is normal or elevated but pH is normal (see Question 1a).
2) To prevent endotracheal intubation and invasive mechanical ventilation in patients with mild to moderate acidosis and respiratory distress, with the aim of preventing deterioration to a point when invasive ventilation would be considered (see Question 1b).
3) As an alternative to invasive ventilation in patients with severe acidosis and more severe respiratory distress (see Question 1b).

Bilevel NIV may also be used as the only method for providing ventilatory support in patients who are not candidates for or decline invasive mechanical ventilation.

**Question 1a: Should NIV be used in ARF due to a COPD exacerbation to prevent the development of respiratory acidosis?**

One randomised study [11] of 52 patients with COPD comparing bilevel NIV to standard oxygen therapy used inclusion criteria of recent onset of shortness of breath and a pH >7.30 (average pH of randomised patients was within the normal range), suggesting that most enrolled patients had not developed acute respiratory acidosis. NIV was poorly tolerated and there was no effect of NIV on intubation rate (8% in NIV arm and 7% in control arm) or mortality (4% in NIV arm and 7% in control arm). However, there was a decrease in Borg dyspnoea score with NIV compared with standard oxygen therapy at 1 h and on day 2. When one outlier was removed from the analysis, there was a statistically significant reduction in hospital length of stay with bilevel NIV compared with the control group (5 versus 7 days).

In three other studies (two randomised controlled trials (RCTs) and one prospective observational study [12–14]) the mean pH was only very mildly acidotic, suggesting again that patients without acute respiratory acidosis were included; none of these studies showed an advantage to bilevel NIV. In a large study (n=342) in which bilevel NIV was started within 24–48 h of admission compared with standard oxygen therapy, in patients with a mean pH at randomisation of 7.35, there was a decrease in patients meeting criteria for intubation with NIV (1.4% versus 4.6%; p=0.002), but no difference in mortality [15]. Subgroup analysis of patients with a pH >7.35 (n=151) showed a beneficial effect of NIV for patients meeting clinical criteria for intubation versus those that did not (9 out of 80 versus 2 out of 71; p=0.045) but not for mortality. However, NIV was started much later than in other studies (24–48 h after admission) and the number of patients deteriorating to the point at which endotracheal intubation was considered necessary was surprisingly high, considering the mild acidosis. The main focus in hypercapnic patients with COPD who are not acidic should be medical therapy and, most importantly, oxygen...
targeted to a saturation of 88–92% [16]. Austin et al. [17] showed a better survival in COPD patients being transferred to hospital when oxygen was delivered to achieve this range of saturation.

**Recommendation**

We suggest NIV not be used in patients with hypercapnia who are not acidotic in the setting of a COPD exacerbation. (Conditional recommendation, low certainty of evidence.)

**Justification**

See forest plots and the evidence profile in the supplementary material for further details regarding included evidence. Pooled analysis was very imprecise but demonstrated that bilevel NIV does not reduce mortality (RR 1.46, 95% CI 0.64–3.35) and decrease the need for intubation (RR 0.41, 95% CI 0.18–0.72). Given the lack of consistent evidence demonstrating benefit in those without acidosis and the potential for harm, the committee decided on a conditional recommendation against bilevel NIV in this setting.

**Question 1b: Should NIV be used in established acute hypercapnic respiratory failure due to a COPD exacerbation?**

**Bilevel NIV to prevent intubation**

Patients with a pH of 7.25–7.35, in the absence of a metabolic cause for the acidosis, would normally not be deemed to require intubation and mechanical ventilation. It is in this group that there is the strongest evidence base to support the use of bilevel NIV [11–34]. An improvement in either pH or respiratory rate, or ideally both, is a good predictor of a successful outcome with NIV; in those that will respond, response is almost universally seen within the first 1–4 h after NIV initiation [35]. Bilevel NIV reduces the sensation of dyspnoea, the need for immediate intubation, and intensive care unit (ICU) and probably hospital length of stay, and improves survival. There is a reduction in both respiratory and nonrespiratory infectious complications [36, 37]. No clinical trials have shown a worse outcome with bilevel NIV compared with standard nonventilatory management, although there was a trend towards increased mortality with NIV in one study that included some patients with COPD, which was attributed to a delay in escalation to invasive mechanical ventilation [14]. Bilevel NIV has been shown to be cost-effective in this patient group [38].

**Bilevel NIV as an alternative to first-line endotracheal intubation**

Two studies have compared bilevel NIV directly with invasive ventilation [24, 27]. The mean pH was 7.20, significantly lower than in the studies discussed earlier. In the study of Conti et al. [24], survival was similar in both groups, but in patients in whom NIV was successful the advantages included shorter duration of ICU and hospital stay, fewer complications, reduced need for de novo oxygen supplementation, and fewer hospital readmissions in the subsequent year. There were important exclusions: the need for urgent intubation due to respiratory arrest, apnoeic episodes, psychomotor agitation requiring sedation, heart rate <60 beats·min$^{-1}$ and systolic arterial pressure <80 mmHg. The study of Jurivic et al. [27] enrolled patients similar to those in the Conti et al. [24] study, but inclusion criteria and primary end-points were not clearly defined. The authors found that invasive ventilation was associated with more rapid improvement in physiological abnormalities in the first few hours, but was also associated with a longer total duration of ventilation and ICU stay. Mortality was similar in the two groups. Patients receiving bilevel NIV had fewer episodes of ventilator-associated pneumonia and less requirement for tracheostomy. Coma has been described as a contraindication to NIV, but in a large case series Diaz et al. [39] showed no difference in outcome between patients with and without hypercapnic coma. Bilevel NIV in the ICU for COPD exacerbation is also cost-effective, with one Canadian study showing a cost savings of CAD3442 per patient admission [40].

**Recommendations**

We recommend bilevel NIV for patients with ARF leading to acute or acute-on-chronic respiratory acidosis (pH ≤7.35) due to COPD exacerbation. (Strong recommendation, high certainty of evidence.)

We recommend a trial of bilevel NIV in patients considered to require endotracheal intubation and mechanical ventilation, unless the patient is immediately deteriorating. (Strong recommendation, moderate certainty of evidence.)

**Justification**

See forest plots and the evidence profile in the supplementary material for further details regarding included evidence. Pooled analysis demonstrated that bilevel NIV decreased mortality (relative risk (RR) 0.63, 95% CI 0.46–0.87; high certainty) and decreased the need for intubation (RR 0.41, 95% CI 0.33–0.52; moderate certainty) in this population. There was also a decrease in nosocomial pneumonia with bilevel NIV (OR 0.26, 95% CI 0.08–0.81; low certainty).
Based on this evidence review, the committee felt the anticipated desirable effects of bilevel NIV in patients with acute hypercapnic respiratory failure due to a COPD exacerbation definitely outweighed the anticipated undesirable effects. This is true across the severity spectrum, but increasing caution must be used towards the more severe end.

**Implementation considerations**

1) Bilevel NIV should be considered when the pH is \( \leq 7.35 \), \( P_{aCO_2} \) is >45 mmHg and the respiratory rate is >20–24 breaths·min\(^{-1}\) despite standard medical therapy.
2) Bilevel NIV remains the preferred choice for patients with COPD who develop acute respiratory acidosis during hospital admission. There is no lower limit of pH below which a trial of NIV is inappropriate; however, the lower the pH, the greater risk of failure, and patients must be very closely monitored with rapid access to endotracheal intubation and invasive ventilation if not improving.

**Question 2a: Should NIV be used in ARF due to cardiogenic pulmonary oedema?**

Over 30 trials have been published on the use of CPAP and/or NIV compared with standard therapy or each other for patients with acute cardiac pulmonary oedema. The majority are small single-centre trials that span a period of 30 years, during which cardiogenic pulmonary oedema management, particularly in the setting of acute coronary syndrome, has evolved along with trial inclusion and exclusion criteria. Patients in cardiogenic shock have been almost universally excluded from trials and thus are not included in our NIV recommendations. Many trials have also excluded patients requiring acute revascularisation and some have excluded patients with acute coronary syndrome.

The pathophysiology of respiratory failure during cardiogenic pulmonary oedema includes decreased respiratory system compliance and alveolar flooding due to high capillary pressure associated or not with left ventricular systolic dysfunction [41]. NIV (including both bilevel and CPAP) in this context has the ability to improve respiratory mechanics and facilitate left ventricular work by decreasing left ventricular afterload [42]. This is facilitated by the decrease in negative pressure swings generated by the respiratory muscles.

In 2008, Gray et al. [43] published the largest multicentre trial from 26 emergency departments, in which 1069 patients were randomised to CPAP, bilevel NIV or standard oxygen therapy. This trial found physiological improvement in the CPAP and bilevel NIV groups compared with the standard group, but no difference in intubation rate or mortality at 7 and 30 days. However, interpretation of the results is limited by the high crossover rate (56 out of 367 patients (15%) in the oxygen group crossed over to bilevel NIV). Subsequently, five systematic reviews [44–48] that have incorporated the data from Gray et al. [43], as well as other new trials, have been published. They consistently conclude that: 1) NIV decreases the need for intubation, 2) NIV is associated with a reduction in hospital mortality, 3) NIV is not associated with increased myocardial infarction (a concern raised by the first study comparing NIV and CPAP [49]), and 4) CPAP and NIV have similar effects on these outcomes.

**Recommendation**

We recommend either bilevel NIV or CPAP for patients with ARF due to cardiogenic pulmonary oedema.

(Strong recommendation, moderate certainty of evidence.)

**Justification**

See forest plots and the evidence profile in the supplementary material for further details regarding included evidence. Pooled analysis demonstrated that NIV decreased mortality (RR 0.80, 95% CI 0.66–0.96; moderate certainty) and decreased the need for intubation (RR 0.60, 95% CI 0.44–0.80; low certainty) in this population. An increase in myocardial infarction was seen in the NIV group although this was based on a very low certainty of evidence (OR 1.18, 95% CI 0.95–1.48). Based on this evidence review, the committee felt the anticipated desirable effects of NIV patients with ARF due to cardiogenic pulmonary oedema definitely outweighed the anticipated undesirable effects. Given the justifiable reluctance to include patients with acute coronary syndrome or cardiogenic shock in studies evaluating NIV for cardiogenic pulmonary oedema, the above recommendation does not apply to these subgroups. The recommendation is inclusive of both bilevel NIV and CPAP, as the current evidence summary demonstrates significant benefit of both interventions compared with standard care, and insufficient evidence to recommend one modality over the other. CPAP has advantages over bilevel NIV of simpler technology, easier synchronisation and potentially less expensive equipment, but the importance of these has not been adequately assessed.

**Question 2b: Should a trial of CPAP prior to hospitalisation be used to prevent deterioration in patients with ARF due to cardiogenic pulmonary oedema?**

Six single-centre RCTs have evaluated the use of CPAP or bilevel NIV to treat cardiogenic pulmonary oedema in the pre-hospital setting. Four trials focused on acute cardiogenic pulmonary oedema and two...
included a subset of cardiogenic pulmonary oedema patients within a general population of patients with ARF (THOMPSON et al. [50]: 44 out of 69 cardiogenic pulmonary oedema; ROESSLER et al. [51]: 25 out of 49 cardiogenic pulmonary oedema). The studies were heterogeneous, with four using CPAP and two using bilevel NIV, and they were conducted in different settings. Five studies were conducted in Europe with a physician supporting the ambulance staff; one study was conducted in Canada, with pre-hospital care and study procedures managed by ambulance staff alone. The intubation rates varied among studies, suggesting potential differences in severity of illness or experience of the ambulance attendants. One study compared early versus delayed NIV [52], while the rest used a control arm of usual medical therapy.

**Recommendation**

We suggest that CPAP or bilevel NIV be used for patients with ARF due to cardiogenic pulmonary oedema in the pre-hospital setting. (Conditional recommendation, low certainty of evidence.)

**Justification**

See forest plots and the evidence profile in the supplementary material for further details regarding included evidence. Pooled analysis demonstrated that NIV decreased mortality (RR 0.88, 95% CI 0.45–1.70; moderate certainty) and decreased the need for intubation (RR 0.31, 95% CI 0.17–0.55; low certainty) in this population. In general, oxygenation and patients’ dyspnoea scores improved more rapidly with CPAP or bilevel NIV compared with control. Some studies showed a reduction in mortality associated with use of bilevel NIV [50], but this effect was inconsistent.

Heterogeneity in trial design, support personnel and patient selection prevent a firm recommendation regarding the use of NIV for cardiogenic pulmonary oedema in the pre-hospital setting. Overall, the results are favourable, but we emphasise the need for appropriate training and adequate infrastructure, including coordination with emergency departments before initiating a programme. More research is needed, including pre-hospital use of bilevel NIV versus CPAP, selection of patients, personnel on ambulances and role of communication with emergency departments.

**Question 3: Should NIV be used in ARF due to acute asthma?**

The main feature of acute asthma is a sudden and reversible episode of bronchoconstriction, leading to an increase in airways resistance that varies in severity. The acute change in mechanical load (mainly resistive) generates hyperinflation, increased respiratory muscle effort and dyspnoea. Hyperinflation also reduces respiratory muscle efficiency and thus the respiratory muscle pump may ultimately become exhausted, leading to hypercapnia [53].

NIV is used, together with conventional pharmacological treatment, with the aim to decrease the respiratory muscle work that is much increased during the episodes of acute bronchoconstriction, to improve ventilation, decrease the sensation of dyspnoea, and ultimately avoid intubation and invasive mechanical ventilation.

Possibly because the magnitude of the problem is small (i.e. episodes of acute asthma requiring ICU admission are uncommon), there is not much published research in this field. One physiological study gives some support to the use of CPAP. This study [54] showed that in asthmatic individuals subjected to histamine challenge causing acute bronchoconstriction, the use of CPAP (average 12 cmH2O), compared with spontaneous breathing, substantially decreased the pressure–time product of the respiratory muscles (an index of energy utilisation), which was explained by a change in mechanics and breathing pattern.

A few uncontrolled studies and RCTs have compared NIV versus routine care in patients with acute asthma [55, 56]. Uncontrolled studies have shown physiological improvements in selected patients, whereas the RCTs and a meta-analysis have not shown differences in clinically relevant outcomes when comparing NIV with usual care [57]. A retrospective observational study by FERNANDEZ et al. [58] described three types of patients admitted in the ICU for acute asthma: those with acute severe near-fatal asthma requiring emergency intubation, those responding well to medical therapy (the majority) and a small subgroup not responding well to medical therapy, who in this study were treated with NIV, mostly with success. RCTs in asthma mostly considered physiological end-points such as improvement in peak flows and suggested some beneficial effects.

In a recent retrospective cohort study [59] conducted in 97 US hospitals during a 4-year period, the use of NIV in patients with acute asthma was 4% (556 out of 13930) and the use of invasive ventilation was 5% (668 out of 13930). Failure rate (defined as intubation) of NIV was 4.7% (26 patients). Hospital mortality rates in those who received invasive mechanical ventilation without a previous trial of NIV, those who failed a NIV attempt and those who succeeded on NIV were 14.5%, 15.4% and 2.3%, respectively.
Recommendation
Given the uncertainty of evidence we are unable to offer a recommendation on the use of NIV for ARF due to asthma.

Justification
See forest plots and the evidence profile in the supplementary material for further details regarding included evidence. Pooled analysis demonstrated that NIV has an unclear effect on mortality, intubation (RR 4.48, 95% CI 0.23–89.23; very low certainty) or ICU length of stay (mean difference 0.3 higher, 95% CI 0.63 lower to 1.23 higher) in this population. NIV does appear to improve forced expiratory volume in 1 s (mean difference 14.02 higher, 95% CI 7.73–20.32 higher; low certainty) and peak expiratory flow (mean difference 19.97 higher, 95% CI 15.01–24.93 higher; low certainty). The lack of evidence precludes making a recommendation regarding the use of NIV for acute asthma. Studies have demonstrated a more rapid reversal of airway obstruction and a reduced need for hospitalisation compared with standard therapy that could reflect a bronchodilator effect of positive airway pressure, but in the absence of any evidence to show a beneficial effect of NIV on intubation rate or survival, the committee considered that the potential desirable effects have not been shown to outweigh the risks of adverse effects. However, given the possibility of overlap between asthma and COPD, bilevel NIV may be considered in a subgroup of patients diagnosed with asthma who are behaving more like patients with COPD (i.e. fixed airway obstruction).

Question 4: Should NIV be used for ARF in immunocompromised patients?
ARF is the main indication for ICU admission in immunocompromised patients. Currently available literature supports the use of NIV as a first-line approach for managing mild to moderate ARF in selected patients with immunosuppression of various aetiologies. Several studies have reported clinical benefits of NIV, although strict monitoring in the ICU and prompt availability of invasive mechanical ventilation are mandatory [60–62]. A large observational multicentre Italian survey investigated the clinical impact of NIV use in 1302 haematological patients admitted to the ICU with ARF [63]. The authors, after a propensity score analysis, confirmed the role of NIV as an independent predictor of survival. Similarly, early CPAP has been reported as a practical, simple and inexpensive method to prevent deterioration of respiratory function and complications in such patients [64]. However, in a recent multicentre randomised trial of 374 immunocompromised subjects, early NIV, compared with standard oxygen, was not associated with clinical benefits in mortality, ICU-acquired infections, duration of mechanical ventilation or length of ICU stay [65].

In addition, a more recent post hoc analysis of immunosuppressed patients enrolled in a larger trial of patients with ARF suggested no benefit of NIV, either for intubation or survival [66].

Recommendation
We suggest early NIV for immunocompromised patients with ARF. (Conditional recommendation, moderate certainty of evidence.)

Justification
See forest plots and the evidence profile in the supplementary material for further details regarding included evidence. Pooled analysis demonstrated that NIV use led to a decrease in mortality (RR 0.68, 95% CI 0.53–0.88; moderate certainty), the need for intubation (RR 0.71, 95% CI 0.58–0.87; moderate certainty) and the rates of nosocomial pneumonia (RR 0.39, 95% CI 0.20–0.76; low certainty) in this population. Based on this evidence review, the anticipated desirable effects of NIV in immunocompromised patients with ARF outweigh undesirable consequences in most settings. The recommendation is inclusive both of bilevel NIV and early CPAP as the current evidence demonstrates the benefit of both interventions compared with standard care. In addition, one recent RCT [67] showed benefits of high-flow nasal cannula oxygen therapy over bilevel NIV with regard to intubation and mortality, and more study is required to determine whether this modality has advantages over NIV in immunocompromised patients with ARF.

Question 5: Should NIV be used in de novo ARF?
De novo respiratory failure refers to respiratory failure occurring without prior chronic respiratory disease. Most patients in this category have hypoxaemic respiratory failure, usually defined as significant hypoxaemia (arterial oxygen tension/inspiratory oxygen fraction ratio (P_{aO_2}/F_{IO_2}) ≤200), tachypnoea (respiratory rate >30–35 breaths·min\(^{-1}\)) and a non-COPD diagnosis (e.g. pneumonia and/or acute respiratory distress syndrome (ARDS)). Although included in some of the studies, patients with cardiogenic pulmonary oedema or with post-operative respiratory distress are not considered here because their pathophysiology is different and the indications and outcomes for NIV differ.
Defining whether a patient has all the features of ARDS [68] may be difficult or impossible in nonintubated patients because precise measurement of the actual inspired fraction of oxygen is unavailable and positive end-expiratory pressure is not used or its level is uncertain (e.g. with high-flow oxygen). Therefore, we considered studies on patients with hypoxaemic respiratory failure, community-acquired pneumonia and ARDS in the same category. NIV is used in these patients with the aims of improving oxygenation, facilitating ventilation, decreasing the work of breathing and dyspnoea, avoiding intubation, and reducing the complications associated with invasive mechanical ventilation.

Limitations of NIV in achieving some of these aims relative to invasive ventilation in patients with de novo ARF include its lack of efficacy in reducing work of breathing, in contrast to hypercapnic respiratory failure where its ability to reduce work of breathing has been clearly demonstrated. In ARDS patients, it has been shown that the use of noninvasive inspiratory pressure support can decrease the inspiratory effort compared with no inspiratory assistance only if sufficient pressure support is added [69]. Of concern, the tidal volume can also be significantly higher during NIV, especially when substantial inspiratory pressure is delivered, and further exacerbated by the high inspiratory demand seen in patients with acute hypoxic respiratory failure [70]. Therefore, the total pressure dissipated to inflate the lungs can be excessive during NIV. Such large transpulmonary pressures and the resulting large tidal volumes may exacerbate lung injury if prolonged over time. It is possible, although not proven, that NIV is especially useful in patients who do not substantially increase their tidal volume, but further work is needed in this area [71].

Invasive ventilation for hypoxaemic respiratory failure clearly reduces work of breathing and permits paralysis if total control of breathing is desired, effects that can redistribute blood flow from the respiratory muscles to other organs in patients with shock and hence help to treat shock itself [72]. The ability of NIV to achieve optimal pressures to reduce the work of breathing reliably in acute hypoxaemic respiratory failure is challenging because the high pressures often required increase air leaks, gastric insufflation and patient intolerance [69]. Thus, the ability to use lung protective ventilator strategies (such as maintaining a low tidal volume of 6 mL·kg\(^{-1}\) of predicted body weight) may be more difficult with NIV than with invasive ventilation [73, 74]. Some evidence even supports the idea that spontaneous ventilation can induce harm similar to ventilator-induced lung injury in situations of severe lung injury [75–77], which raises a note of caution when using NIV that combines spontaneous effort with ventilator support.

Hypoxaemia and high work of breathing return immediately when NIV is removed, explaining the risk associated with NIV interruptions. This may be ameliorated, as suggested by some recent trials, by the use of high-flow nasal cannula therapy (using a specialised nasal cannula to deliver heated and humidified oxygenated gas at flows between 30 and 60 L·min\(^{-1}\)) during breaks or using longer sessions of NIV [78]. Also, the duration of NIV and its tolerance may depend on the type of interface used; recent evidence suggests that the use of a helmet may offer better tolerance over prolonged periods [79–82].

Potential uses of NIV for de novo ARF include as a preventive strategy for avoiding intubation. One pilot study on patients with “early” ARDS (\(P_{A\text{O}_2}/P_{F\text{O}_2} \geq 200\) and \(\leq 300\)) showed avoidance of intubation and reduced cytokine levels as favourable outcomes [83]. However, this study has not been replicated. NIV has also been studied as an alternative to intubation, with occasional reports showing benefit [84]. Positive studies on hypoxaemic, nonhypercapnic respiratory failure, mainly caused by community- or hospital-acquired pneumonia, have enrolled carefully selected patients who are cooperative with no associated major organ dysfunction, cardiac ischaemia or arrhythmias, and with no limitations in clearing secretions [29, 60, 85–87], which may explain the benefits seen.

Until recently, almost all studies on NIV for de novo ARF compared it with oxygen delivered with standard air entrainment (Venturi masks) or reservoir masks. Recently, high-flow nasal cannula therapy has been shown to offer several advantages compared with NIV, including better tolerance and dead space reduction [88]. One recent RCT reported a survival benefit of high-flow nasal cannula over standard oxygen therapy and bilevel NIV, although the primary end-point of intubation was not significantly different [67]. Although high-flow nasal cannula therapy is not specifically addressed in these recommendations, it may assume an important role in the therapy of de novo respiratory failure in the future.

The main risk of NIV for the indication of de novo ARF is to delay a needed intubation [86]. Early predictors of NIV failure include higher severity score, older age, ARDS or pneumonia as the aetiology for respiratory failure, or a failure to improve after 1 h of treatment [89]. Although the reasons for a poorer outcome are not completely understood, patients with NIV failure have higher tidal volumes before intubation [71] and develop more complications after intubation [90]. Studies have shown that NIV failure is an independent risk factor for mortality specifically in this population, although careful patient selection seems to reduce this risk [91, 92].

https://doi.org/10.1183/13993003.02426-2016
Recommendation
Given the uncertainty of evidence we are unable to offer a recommendation on the use of NIV for de novo ARF.

Justification
See forest plots and the evidence profile in the supplementary material for further details regarding included evidence. Pooled analysis demonstrated that NIV use led to a decrease in mortality (RR 0.83, 95% CI 0.65–1.05) and the need for intubation (RR 0.75, 95% CI 0.63–0.89), although these were both based on a low certainty of evidence. In highly selected cooperative patients with isolated respiratory failure, NIV has been shown in experienced hands to prevent intubation [85]. The overall effect in the studies is positive on this end-point, but not for other end-points such as mortality. Specific risks have been described with NIV and there is not enough evidence to recommend its use. Further research is needed and this question requires re-appraisal in the future. Considering that some studies have identified populations likely to succeed with NIV, a trial of NIV might be offered to a patient with hypoxaemic respiratory failure, community-acquired pneumonia or early ARDS if they are being managed by an experienced clinical team, are carefully selected (no contraindications such as abnormal mental status, shock or multiorgan system failure), are closely monitored in the ICU, reassessed early after starting NIV and intubated promptly if they are not improving.

Question 6: Should NIV be used in ARF in the post-operative setting?
Surgery, particularly that approaching the diaphragm, anaesthesia and post-operative pain may all have deleterious effects on the respiratory system, causing hypoxaemia, a decrease in lung volume and atelectasis due to diaphragm dysfunction [93]. These modifications of respiratory function occur early after surgery and diaphragm dysfunction may last up to 7 days, leading to an important deterioration in arterial oxygenation [94]. Maintenance of adequate oxygenation and avoidance of symptoms of respiratory distress in the post-operative period are of major importance, especially when pulmonary complications such as ARF occur [95, 96].

Both bilevel NIV and CPAP are frequently used in these clinical situations. Imaging studies have shown that the use of NIV may increase lung aeration and decrease the amount of atelectasis during the post-operative period of patients undergoing major abdominal surgery [93]. Physiological studies have shown that CPAP and bilevel NIV are effective at improving lung aeration and arterial oxygenation and decreasing the amount of atelectasis without adverse haemodynamic effects during the post-operative period after extubation [93, 97].

Supra-diaphragmatic surgery
One RCT demonstrated that in patients who developed respiratory failure during the post-operative period of lung cancer resection, NIV decreased the need for re-intubation and reduced hospital mortality [98]. STEPHAN et al. [96] reported that, in 830 patients following cardiothoracic surgery with or at risk for respiratory failure, the use of high-flow nasal cannula therapy compared with intermittent NIV did not result in a worse rate of treatment failure defined as need for re-intubation.

Abdominal and/or pelvic surgery
In a prospective observational study in patients who had respiratory failure after abdominal surgery, JABER et al. [99] reported that the use of NIV resulted in avoidance of intubation in 67% cases, and a reduction in the hospital length of stay and mortality, compared with intubated patients. In a randomised trial on 40 patients undergoing solid organ transplantation (mainly liver transplantation) and developing post-operative respiratory failure, ANTONELLI et al. [60] found that NIV improved oxygenation and decreased the need for tracheal intubation compared with conventional therapy. SQUADRONE et al. [100] evaluated the use of helmet-CPAP after abdominal surgery in 209 patients who developed hypoxaemia without respiratory symptoms immediately after extubation. Their early use of CPAP significantly decreased the incidence of re-intubation from 10% to 1% (p=0.005). JABER et al. [95] recently reported the results of a multicentre RCT including 298 patients with hypoxaemic ARF following abdominal surgery. The use of NIV compared with standard oxygen therapy reduced the risk of tracheal re-intubation within 7 days (46% versus 33%; p=0.03) and the incidence of healthcare-associated infections (31% versus 49%; p=0.003).

Recommendation
We suggest NIV for patients with post-operative ARF. (Conditional recommendation, moderate certainty of evidence.)
Two RCTs in patients with advanced cancer have evaluated the efficacy of NIV in reducing dyspnoea. Hui et al. showed a similar improvement in dyspnoea scores between NIV and high-flow oxygen, while a larger multicentre study demonstrated a significantly greater reduction in breathlessness using NIV, especially in the hypercapnic subgroup of patients. Interestingly, the latter investigation showed that NIV might reduce the dose of morphine necessary to palliate dyspnoea, maintaining better cognitive function. Overall, NIV had a similar rate of acceptance by patients compared with oxygen therapy (~60%).

Question 7: Should NIV be used in patients with ARF receiving palliative care?

In palliative care, the intensity of breathlessness frequently worsens as death approaches. Patients and their families expect symptomatic relief of this devastating symptom. Clinicians often respond by providing opioids, a highly effective treatment for this symptom but with a number of potentially undesirable side-effects, including excessive sedation.

The Society of Critical Care Medicine charged a Task Force to provide guidance for the use of NIV in palliative care settings. Apart from type 1 patients in whom NIV is a life support with no limitation of therapy, the authors identified distinct goals for patients in palliative settings; identifying a “type 2” scenario in which a patient has decided to forego intubation, but still wants to receive salvage NIV therapy with the goal of surviving the hospitalisation. “Type 3” patients seek symptom alleviation, mainly dyspnoea, and survival is not a goal for these patients. Most of these type 3 patients, with the support of their families, are interested in ensuring comfort while dying, but some may also be interested in prolonging their lives for a few hours while maintaining cognition and the ability to communicate as they await relatives or to finalise their affairs. In this context, NIV would be considered effective if it improves breathlessness and respiratory distress without causing other troubling consequences, such as mask discomfort or unduly prolonging life. One large observational study on patients using NIV in ICUs found that those in whom NIV was a ceiling for therapy had the same quality of life as patients with no discomfort or unduly prolonging life. Before initiating NIV in post-operative patients with ARF, surgical complications such as anastomotic leak or intra-abdominal sepsis should be addressed first. Then, if the patient is cooperative and able to protect the airway, NIV can be initiated safely.

Recommendation

We suggest offering NIV to dyspnoic patients for palliation in the setting of terminal cancer or other terminal conditions. (Conditional recommendation, moderate certainty of evidence.)

Justification

See forest plots and the evidence profile in the supplementary material for further details regarding included evidence. Pooled analysis demonstrated that NIV use led to a decrease in mortality (RR 0.28, 95% CI 0.09–0.84; moderate certainty), the need for intubation (RR 0.27, 95% CI 0.12–0.61; low certainty) and the incidence of nosocomial pneumonia (RR 0.20, 95% CI 0.04–0.88; very low certainty) in this post-operative population. Both CPAP and bilevel NIV counter the pathophysiological mechanisms predisposing to post-operative respiratory failure. The evidence suggests that both are effective to improve clinical outcomes in patients with post-operative ARF, particularly those with abdominal and thoracic surgery, but also after cardiac surgery. NIV reduces intubation rates, nosocomial infections, lengths of stay, morbidity and mortality. Before initiating NIV in post-operative patients with ARF, surgical complications such as anastomotic leak or intra-abdominal sepsis should be addressed first. Then, if the patient is cooperative and able to protect the airway, NIV can be initiated safely.

Question 8: Should NIV be used in ARF due to chest trauma?

The utility of bilevel NIV or CPAP for treatment of respiratory failure in chest trauma patients has been investigated in three RCTs and in a small subgroup of patients enrolled in a fourth trial [85].
Two of these studies compared NIV versus supplemental oxygen [85, 107], while the other two used invasive mechanical ventilation as control [105, 106].

A single-centre RCT randomised 69 trauma patients with at least four unilateral rib fractures to receive either CPAP or invasive mechanical ventilation [105]. Two out of 33 patients in the CPAP group died in hospital compared with none of the invasively ventilated patients (p>0.05). Patients randomised to CPAP had a significantly shorter ICU length of stay and less nosocomial pneumonia. A second RCT randomised 52 patients with multiple rib fractures and hypoxia to either CPAP or invasive ventilation [106], but no statistical difference was observed in any of the outcomes considered.

A third study randomised chest trauma patients with any injury and respiratory failure to NIV or high-flow oxygen therapy (>10 L·min−1) [107]. The study was stopped early after a second interim analysis after 50 patients had been included. Patients enrolled in this study were significantly more hypoxaemic (mean $P_{aO2}/FiO2$ 100±34.5) than those in other studies. Significantly fewer intubations were performed in patients randomised to receive NIV (RR 0.20, 95% CI 0.05–0.87), resulting in a significant decrease in ICU length of stay with NIV.

The last study was a multicentre RCT that randomised patients with respiratory failure from multiple aetiologies to receive NIV versus standard oxygen therapy [85]. 17 out of 105 hypoxaemic patients (16%) that were enrolled had a presenting diagnosis of chest trauma. Outcome data for mortality and intubation was presented for the chest trauma subgroup, but no significant difference between groups was seen for either of these outcomes.

**Recommendation**

We suggest NIV for chest trauma patients with ARF. (Conditional recommendation, moderate certainty of evidence.)

**Justification**

See forest plots and the evidence profile in the supplementary material for further details regarding included evidence. Pooled analysis demonstrated that NIV use led to a decrease in mortality (RR 0.55, 95% CI 0.22–1.41; moderate certainty), the need for intubation (OR 0.21, 95% CI 0.06–0.74; moderate certainty) and the incidence of nosocomial pneumonia (OR 0.29, 95% CI 0.13–0.64; low certainty) in this population. There was also a decrease in ICU length of stay (mean difference 2.47 lower, 95% CI 1.5–3.45 lower). The dearth of studies, heterogeneity in trial design, different comparators (i.e. oxygen or invasive ventilation), different severities of patients at enrolment and different causes of ARF (i.e. rib fracture or flail chest) prevent us from making a definitive recommendation. However, given the positive overall results, we suggest a cautious NIV trial in these patients when pain is controlled and hypoxaemia not severe.

**Question 9: Should NIV be used in ARF due to pandemic viral illness?**

The use of NIV for severe acute respiratory syndrome and other airborne diseases has been assessed in several observational studies and remains controversial. These studies reported NIV failure rates of 30% and 33% [108, 109], with no evidence of viral spread to caregivers who took appropriate precautions. More recently, NIV was also used in patients with ARF due to influenza A H1N1 infection, with failure rates ranging between 13% and 77% [110–112]. However, no randomised clinical trial has assessed the efficacy of NIV in such pandemics.

**Recommendation**

Given the uncertainty of evidence we are unable to offer a recommendation for this question.

**Justification**

Despite the lack of any RCTs, the positive data from most of the observational studies and the controversial issue of possible increased risk of passing infection on to caregivers, we consider the prior recommendations against the use of NIV for pandemics as unsupportable. Although a cautious NIV trial in carefully selected patients at experienced centres, in a protected environment (i.e. negative pressure rooms), may be reasonable, further research is needed before a recommendation is possible.

**Question 10: Should NIV be used in ARF following extubation from invasive mechanical ventilation?**

Re-intubation following extubation failure is a major clinical problem. Rates of extubation failure as high as 23.5% have been reported [113]. In contrast to patients who are successfully extubated, those who are re-intubated because of post-extubation respiratory failure are characterised as having a worse prognosis,
even after controlling for level of severity, which suggests a direct adverse effect of re-intubation itself on patient outcomes [114].

As re-intubation is associated with increased mortality, any strategy aimed at reducing the rate of post-extubation respiratory failure and avoiding re-intubation deserves consideration. NIV might be a means to avoid re-intubation either by treating post-extubation respiratory failure when it develops or preventing it from developing at all by instituting NIV immediately after extubation. As these are different questions, they are best considered and discussed separately. For the sake of clarity, post-operative patients are not considered in this section.

**Question 10a: Should NIV be used to prevent respiratory failure post-extubation?**

The benefits of early application of NIV soon after extubation have been assessed in unselected patients (*i.e.* any patients after planned extubation) and in at-risk patients. For most included studies, at-risk included patients >65 years or those with underlying cardiac or respiratory disease.

**Unselected patients**

In 1999, Jiang et al. [115] enrolled 93 consecutive patients following planned (60.2%) or unplanned (39.8%) extubation, who were randomised either to preventive NIV (treatment group) or standard treatment (control group). They found no difference in the rate of re-intubation between the two groups. In the 37 patients in whom extubation was unplanned, the re-intubation rate was 38% compared with 11% in the 56 patients undergoing planned extubation [115]. More recently, Su et al. [116] enrolled 406 unselected patients extubated after passing a spontaneous breathing trial (SBT). Consistent with the previous study [115], compared with standard treatment, NIV did not decrease the rate of re-intubation. ICU mortality also was not significantly different [116]. Overall, in unselected patients post-extubation, NIV provides no benefit compared with standard oxygen therapy.

**At-risk patients**

Two multicentre RCTs evaluated whether NIV could prevent re-intubation when applied immediately after planned extubation to selected patients at high risk of post-extubation respiratory failure [117, 118]. Nava et al. [117] enrolled 97 patients who were randomised 1 h after extubation, following a successful SBT, to receive either NIV (minimum 8 h·day$^{-1}$ for 2 days) or standard treatment (oxygen therapy). NIV reduced the rate of re-intubation, which resulted in a reduced ICU mortality. Ferrer et al. [118] randomised 162 patients considered to be at risk for extubation failure to either NIV (near-continuously for 24 h) or oxygen therapy only. NIV decreased the number of patients developing post-extubation respiratory failure and ICU mortality; however, the rate of re-intubation, ICU and hospital length of stay, and hospital mortality were not significantly different between the two groups. A post hoc analysis showed that NIV improved hospital and 90-day survival in the subgroup of patients who developed hypercapnia during the SBT prior to extubation [118]. Subsequent to these observations, the same authors enrolled a select group of 106 patients with chronic respiratory disorders developing hypercapnia during the SBT to investigate the benefits of NIV, as opposed to oxygen therapy alone, after extubation [119]. The rate of respiratory failure after extubation was lower in the NIV group than in the controls. While ICU and hospital mortality were not different between the treatment and control groups, the 90-day survival rate was significantly improved in the NIV group, as opposed to controls.

Two small single-centre trials (40 patients each) also randomised patients to NIV or standard treatment after planned extubation [120, 121]. Kihlani et al. [120] enrolled COPD patients and found no differences in intubation rate or ICU and hospital lengths of stay. In a small group of patients for whom the only inclusion criterion was mechanical ventilation for >72 h because of ARF, predominantly secondary to COPD exacerbations, Ornico et al. [121] found a reduction in re-intubation and death in the NIV group.

**Recommendations**

We suggest that NIV be used to prevent post-extubation respiratory failure in high-risk patients post-extubation. (Conditional recommendation, low certainty of evidence.)

We suggest that NIV should not be used to prevent post-extubation respiratory failure in non-high-risk patients. (Conditional recommendation, very low certainty of evidence.)

**Justification**

See forest plots and the evidence profile in the supplementary material for further details regarding included evidence. Pooled analysis demonstrated that NIV use led to a decrease in mortality (RR 0.41, 95% CI 0.21–0.82; moderate certainty) and the need for intubation (RR 0.75, 95% CI 0.49–1.15; low certainty). There are
some inconsistencies regarding the criteria for considering patients at high risk of extubation failure. Recent work reports that patients >65 years and with underlying cardiac or respiratory disease are at high risk for extubation failure with a re-intubation rate >30% if both comorbidities are present and >20% if one of the two is present [122]. Early NIV after planned extubation decreases both intubation rate and mortality in patients at high risk of extubation failure. Patients with an unplanned extubation are a higher risk group and further studies should specifically address the use of NIV in this group.

**Question 10b: Should NIV be used in the treatment of respiratory failure that develops post-extubation?**

Following the positive findings of case series and case–control studies, two RCTs compared NIV with conventional treatment (oxygen therapy) in patients who developed respiratory failure after planned extubation [123, 124].

Kieman et al. [123] investigated the role of NIV, compared with standard treatment, to avert re-intubation in 78 patients who developed respiratory distress, defined as tachyypnoea and use of respiratory accessory muscles, within 48 h of extubation. This single-centre RCT did not find any beneficial effect of NIV on re-intubation, ICU and hospital mortality or length of ICU and hospital stay. In a multicentre RCT, Esteban et al. [124] enrolled 221 patients with respiratory failure defined by at least two of the following: hypoxaemia, respiratory acidosis, tachypnoea or respiratory distress within 48 h of extubation; patients were randomised to NIV or standard treatment. The trial showed no benefit from NIV on re-intubation and ICU length of stay. ICU mortality was higher in the NIV group, suggesting that it was harmful, probably by delaying intubation. A meta-analysis performed by Lin et al. [125] in 2014 on these two studies indicates no benefit of NIV compared with standard treatment with respect to re-intubation rate and mortality.

**Recommendation**

We suggest that NIV should not be used in the treatment of patients with established post-extubation respiratory failure. (Conditional recommendation, low certainty of evidence.)

**Justification**

See forest plots and the evidence profile in the supplementary material for further details regarding included evidence. Pooled analysis demonstrated that NIV use led to an increase in mortality (RR 1.33, 95% CI 0.83–2.13, low certainty), with an uncertain effect on intubation (RR 1.02, 95% CI 0.83–1.25, low certainty). The use of NIV to avoid re-intubation in patients with overt respiratory distress and/or respiratory failure consequent to failed planned extubation is not advisable. However, because of some limitations in the trials this statement is not definitive. In particular, in the study by Esteban et al. [124], the use of NIV as rescue therapy had a much higher success rate than in those who received it as initial treatment, there was a lack of experience of NIV in some participating centres and there was very limited enrolment rate at some sites. In addition, both the Kieman et al. [123] and Esteban et al. [124] studies had few COPD patients (~10%), so this recommendation may not apply to post-extubation COPD patients with respiratory failure. Further studies are needed.

**Question 11: Should NIV be used to facilitate weaning patients from invasive mechanical ventilation?**

NIV has been shown to be as effective as invasive mechanical ventilation in improving breathing pattern, reducing inspiratory effort and maintaining adequate gas exchange during the weaning phase in selected patients intubated and ventilated for hypercapnic ARF [126]. Based on this physiological rationale, NIV has been utilised in these patients as a means to speed up the weaning process, while avoiding the side-effects and complications of invasive ventilation.

Burns et al. [127] identified 16 RCTs enrolling a total of 994 participants, mostly with COPD. Of the 16 studies, nine included only patients with COPD [128–136], six included mixed populations (predominantly hypercapnic) [137–142] and one small pilot study included only hypoxaemic patients [143]. Compared with conventional weaning using either a progressive reduction of inspiratory support or SBTs, NIV was associated with a significant decrease in mortality (RR 0.53, 95% CI 0.36–0.80; 994 patients). The pooled data showed a significant reduction in the proportion of weaning failures with NIV (RR 0.63, 95% CI 0.42–0.96). There were also significant reductions in ventilator-associated pneumonia (RR 0.25, 95% CI 0.15–0.43; 935 patients), ICU (mean difference −5.59 days, 95% CI −7.90 to −3.28) and hospital (mean difference −6.04 days, 95% CI −9.22 to −2.87) length of stay, total duration of mechanical ventilation (mean difference −5.64 days, 95% CI −9.50 to −1.77), and duration of invasive ventilation (mean difference −7.44 days, 95% CI −10.34 to −4.55). Weaning time and weaning failure were no different between NIV and conventional weaning (mean difference −0.25 days, 95% CI −2.06 to 1.56).
Of the 16 studies, the largest multicentre RCT (including 208 patients randomised to three groups receiving either conventional weaning through the endotracheal tube, early extubation followed by NIV or early extubation followed by oxygen therapy) resulted in similar rates of re-intubation in all three groups (30%, 32%, and 37%, respectively; p-value nonsignificant) [138]. However, the cumulative rates of weaning success were significantly better in patients randomised to the NIV group. The reason for this discrepancy in re-intubation versus weaning success was related to the use of NIV as a rescue treatment for patients who failed conventional weaning and oxygen therapy.

**Recommendations**

We suggest NIV be used to facilitate weaning from mechanical ventilation in patients with hypercapnic respiratory failure. (Conditional recommendation, moderate certainty of evidence.)

We do not make any recommendation for hypoxaemic patients.

**Justification**

See forest plots and the evidence profile in the supplementary material for further details regarding included evidence. Pooled analysis demonstrated that NIV use led to a decrease in mortality (RR 0.54, 95% CI 0.41–0.70; moderate certainty), weaning failure (RR 0.61, 95% CI 0.48–0.79; low certainty) and the incidence of ventilator-associated pneumonia (RR 0.22, 95% CI 0.15–0.32; low certainty) in this population. Based on this evidence review, the committee felt the anticipated desirable effects of NIV applied immediately following extubation in patients with an acute COPD exacerbation who fail the SBT outweigh the anticipated undesirable effects. The intricacies of using NIV for weaning are more difficult (compared with other indications) and therefore the committee felt more comfortable with a conditional, rather than a strong, recommendation. Centres must have adequate experience using NIV in this setting before considering use.

**Conclusions**

Based on a systematic review of the literature, and building upon previous meta-analyses and guidelines, we make recommendations regarding the current use of NIV for various forms of respiratory failure encountered in acute care settings (table 2). Our recommendations are largely in line with guidelines published within the past 15 years, but there have been incremental alterations as new studies and information have become available. We anticipate that some of these recommendations will change in the future as new studies are completed, especially regarding the use of NIV as opposed to other emerging technologies such as high-flow nasal cannula therapy and extracorporeal CO₂ removal. We emphasise that these guidelines should not be interpreted as absolute and should be implemented based on patient factors, including individual values and preferences, only in combination with clinical judgement. We also refer readers to the supplementary material in which we address a number of issues related to practical application of NIV that have not been subject to the GRADE process.

**References**


O'Driscoll BR, Howard LS, Davison AG. BTS guideline for emergency oxygen use in adult patients. Thorax 2008; 63: Suppl. 6, vi–vi68.


Preventing postoperative pulmonary complications. The role of the anesthesiologist.


Chen J, Qiu D, Tao D. [Time for extubation and sequential noninvasive mechanical ventilation in COPD patients with exacerbated respiratory failure who received invasive ventilation.] Zhonghua Jie He He Hu Xi Za Zhi 2001; 24: 99–100.


Gamal MR, Ashraf ZM, Rania NM. Noninvasive ventilation in the weaning of patients with acute-on-chronic respiratory failure due to COPD. Chest 2004; 126: Suppl. 4, 755S.


